JP2001505930A - 皮膚への局所的施用のためのホルモン代償療法薬剤 - Google Patents
皮膚への局所的施用のためのホルモン代償療法薬剤Info
- Publication number
- JP2001505930A JP2001505930A JP52411099A JP52411099A JP2001505930A JP 2001505930 A JP2001505930 A JP 2001505930A JP 52411099 A JP52411099 A JP 52411099A JP 52411099 A JP52411099 A JP 52411099A JP 2001505930 A JP2001505930 A JP 2001505930A
- Authority
- JP
- Japan
- Prior art keywords
- active drug
- weight
- hormone
- skin
- dioxolane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Prostheses (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 全組成物の重量に基づいて 約0.1から約10%までのホルモン様活性薬物; C7〜C14−ヒドロカルビル置換された1,3−ジオキソラン、1,3−ジオ キサンまたはアセタールを含んでなる約2から20%までの皮膚透過増強剤; 0ないし約25%のプロピレングリコール; エタノール、イソプロパノール及びそれらの混合物よりなる群から選択される 約35%から75%までの揮発性アルコール; 0ないし約35%の水;及び 場合により、皮膚に施用した場合に流出を避けるかまたは最小限にするように 組成物を増粘するために有効なゲル化剤 を含んでなるホルモン様活性薬物の経皮送達のためのアルコールまたは水性アル コールの局所用組成物。 2. 該ゲル化剤が存在し、そして約4%までのセルロース系増粘剤を含んで なる請求の範囲1の局所用組成物。 3. 重量に基づいて、 約1から約6%までのホルモン様活性薬物; 約2から15%までの該増強剤; 5ないし約22%の1,2−プロピレングリコール; 約40から75%までのエタノール、イソプロパノールまたはそれらの混合物 ; 0ないし約25%の水;及び 0ないし約3%のセルロース系増粘剤 を含んでなる請求の範囲2の局所用組成物。 4. 重量に基づいて、 約1.0から約4%までのホルモン様活性薬物; 約5から10%までの該増強剤; 5ないし約20%の1,2−プロピレングリコール; 約50から75%までのエタノール、イソプロパノールまたはそれらの混合物 ; 0ないし約25%の水;及び 0ないし約2%のセルロース系増粘剤 を含んでなる請求の範囲2の局所用組成物。 5. ホルモン様活性薬物がエストロゲン、プロゲステロンもしくはアンドロ ゲンまたはそれらの混合物である請求の範囲2の局所用組成物。 6. ホルモン様活性薬物がテストステロンを含んでなる請求の範囲5の局所 用組成物。 7. ホルモン様活性薬物がエストラジオールを含んでなる請求の範囲5の局 所用組成物。 8. ホルモン様活性薬物がプロゲステロンを含んでなる請求の範囲5の局所 用組成物。 9. 70:10−20:20−10の重量比のエタノール/プロピレングリ コール/水担体系;及び重量で約10%の2−n−ノニル−1,3−ジオキソラ ンを含んでなる請求の範囲6の局所用組成物。 10. 70:10−20:20−10の重量比のエタノール/プロピレング リコール/水担体系;及び重量で約5から約10%までの2− n−ノニル−1,3−ジオキソランを含んでなる請求の範囲7の局所用組成物。 11. 重量で約10%の2−n−ノニル−1,3−ジオキソランを含んでな る請求の範囲13の局所用組成物。 12. 70:10−20:20−10の重量比のエタノール/プロピレング リコール/水担体系;及び重量で約5から約10%までの2−n−ノニル−1, 3−ジオキソランを含んでなる請求の範囲8の局所用組成物。 13. 重量で約10%の2−n−ノニル−1,3−ジオキソランを含んでな る請求の範囲15の局所用組成物。 14. エタノール、イソプロパノール及びそれらの混合物よりなる群から選 択される低級アルコール、3個から6個までの炭素原子を有する1,2−アルキ ルジオール、並びに水を50−80:5−20:5−40の混合比で含んでなる ビヒクル中に治療的に有効な量のホルモン様活性薬物を含んでなるアルコールま たは水性アルコールの組成物を患者の皮膚に局所的に施用することを含んでなる ホルモン様活性薬物のそれを必要とする患者への経皮投与方法で、該ビヒクルが 約70から90重量%までの組成物、並びにヒドロカルビル基が7個から14個 までの炭素原子を有する2−ヒドロカルビル−1,3−ジオキソラン、2−ヒド ロカルビル−1,3−ジオキサン及びヒドロカルビル置換された−アセタールよ りなる群から選択される約5から約20重量%までの皮膚透過を高める化合物を 含んでなる方法。 15. ホルモン様活性薬物がエストロゲン、プロゲステロン、アンドロゲン またはそれらの混合物よりなる群から選択される請求の範囲9 のホルモン様活性薬物の経皮投与方法。 16. 薬物がテストステロン、プロゲステロン及びエストラジオールよりな る群から選択される請求の範囲9のホルモン様活性薬物の経皮投与方法。 17. ホルモン様活性薬物がテストステロンである請求の範囲9の方法。 18. ホルモン様活性薬物がエストラジオールである請求の範囲9の方法。 19. ホルモン様活性薬物がプロゲステロンである請求の範囲9の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/953,014 US5968919A (en) | 1997-10-16 | 1997-10-16 | Hormone replacement therapy drug formulations for topical application to the skin |
US08/953,014 | 1997-10-16 | ||
PCT/US1998/020895 WO1999020257A1 (en) | 1997-10-16 | 1998-10-02 | Hormone replacement therapy drug formulations for topical application to the skin |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001505930A true JP2001505930A (ja) | 2001-05-08 |
Family
ID=25493463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52411099A Ceased JP2001505930A (ja) | 1997-10-16 | 1998-10-02 | 皮膚への局所的施用のためのホルモン代償療法薬剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US5968919A (ja) |
EP (1) | EP0971705B1 (ja) |
JP (1) | JP2001505930A (ja) |
AT (1) | ATE288744T1 (ja) |
CA (1) | CA2260185C (ja) |
DE (1) | DE69828958T2 (ja) |
DK (1) | DK0971705T3 (ja) |
ES (1) | ES2238094T3 (ja) |
PT (1) | PT971705E (ja) |
WO (1) | WO1999020257A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005519961A (ja) * | 2002-03-11 | 2005-07-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 継続的スルファターゼ阻害プロゲストゲンホルモン補充療法 |
WO2009037813A1 (ja) | 2007-09-20 | 2009-03-26 | Shiseido Company, Ltd. | 経皮吸収製剤 |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US5942545A (en) * | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
US6582683B2 (en) | 2000-01-04 | 2003-06-24 | Skinvisible Pharmaceuticals, Inc. | Dermal barrier composition |
AU2001242024A1 (en) * | 2000-07-19 | 2002-02-05 | W. Roy Knowles | Hair loss prevention |
US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
ATE355854T1 (de) | 2000-08-03 | 2007-03-15 | Antares Pharma Ipl Ag | Neue zusammensetzung zur transdermalen und/oder transmukosalen wirkstoffanwendung mit geeignetem therapeutischen spiegel |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US20030139384A1 (en) * | 2000-08-30 | 2003-07-24 | Dudley Robert E. | Method for treating erectile dysfunction and increasing libido in men |
US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
EP1322336B1 (en) * | 2000-08-30 | 2013-07-03 | Unimed Pharmaceuticals, LLC | Method of increasing testosterone and related steroid concentrations in women |
US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
US20020107230A1 (en) * | 2000-12-22 | 2002-08-08 | Waldon R. Forrest | Methods and formulations for the treatment of female sexual dysfunction |
ES2283446T3 (es) * | 2000-12-22 | 2007-11-01 | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL | Composicion de gel basada en alcohol para el tratamiento del hipogonadismo por administracion transescrotal. |
US20050209208A1 (en) * | 2001-04-25 | 2005-09-22 | The Regents Of The University Of California | Use of estriol and other estranes, estrogens and estrogen receptor active compositions in the treatment of psoriasis and other autoimmune disorders |
US7244703B2 (en) | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
US6756059B2 (en) * | 2001-08-20 | 2004-06-29 | Skinvisible Pharmaceuticals, Inc. | Topical composition, topical composition precursor, and methods for manufacturing and using |
US20030191096A1 (en) * | 2002-04-03 | 2003-10-09 | Leonard Thomas W. | Method of hormonal therapy |
MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
EA009024B1 (ru) * | 2002-06-25 | 2007-10-26 | АКРУКС ДиДиЭс ПиТиУай ЭлТиДи | Фармацевтическая композиция для чрескожной доставки активного агента (варианты) |
AUPS317302A0 (en) * | 2002-06-25 | 2002-07-18 | Drug Delivery Solutions Pty Ltd | Metastable pharmaceutical compositions |
US20040126339A1 (en) * | 2002-12-31 | 2004-07-01 | Roszell James A. | Sunscreen composition and methods for manufacturing and using a sunscreen composition |
WO2004078092A2 (en) * | 2003-02-28 | 2004-09-16 | Waikiwi Corporation | Cream dispenser |
DE10314976A1 (de) | 2003-04-02 | 2004-10-14 | Bayer Healthcare Ag | Verbesserte Penetration von Wirkstoffen in Zellen und Organe |
US20040259852A1 (en) * | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
US8883769B2 (en) * | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
US20050036953A1 (en) * | 2003-08-13 | 2005-02-17 | Moshe Arkin | Topical compositions of ammonium lactate |
US20050042182A1 (en) * | 2003-08-13 | 2005-02-24 | Moshe Arkin | Topical compositions of urea |
US20050037040A1 (en) * | 2003-08-13 | 2005-02-17 | Moshe Arkin | Topical compositions of urea and ammonium lactate |
US20050020552A1 (en) * | 2003-07-16 | 2005-01-27 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20050042268A1 (en) * | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20050025833A1 (en) * | 2003-07-16 | 2005-02-03 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
EP1670433B1 (en) | 2003-10-10 | 2011-11-23 | Antares Pharma IPL AG | Transdermal pharmaceutical formulation for minimizing skin residues |
EP1706128B1 (en) | 2003-12-08 | 2010-07-21 | CPEX Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for insulin treatment |
US7425340B2 (en) * | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
EP1634583A1 (en) * | 2004-09-09 | 2006-03-15 | Laboratoires Besins International | Testosterone gels comprising propylene glycol as penetration enhancer |
MX2007002814A (es) * | 2004-09-09 | 2007-05-16 | Besins Int Lab | Geles de testosterona comprendiendo propilenglicol como mejorador de penetracion. |
US20060110415A1 (en) * | 2004-11-22 | 2006-05-25 | Bioderm Research | Topical Delivery System for Cosmetic and Pharmaceutical Agents |
WO2007124250A2 (en) | 2006-04-21 | 2007-11-01 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
WO2006125642A1 (en) | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
BRPI0611134A2 (pt) * | 2005-06-03 | 2010-08-17 | Acrux Dds Pty Ltd | método e composição para liberação transdérmica de fármaco |
CN101287470B (zh) | 2005-10-12 | 2012-10-17 | 优尼麦德药物股份有限公司 | 改良的睾酮凝胶及使用方法 |
WO2008066618A2 (en) * | 2006-10-20 | 2008-06-05 | Skinvisible Pharmaceuticals, Inc. | Antifungal composition and methods for using |
MX2009007366A (es) | 2007-01-11 | 2009-07-16 | Acrux Dds Pty Ltd | Implemento para untar. |
US8128913B1 (en) | 2007-12-06 | 2012-03-06 | Skinvisible Pharmaceuticals, Inc. | Sunscreen composition with enhanced UV-A absorber stability and methods |
US8299122B2 (en) * | 2008-04-14 | 2012-10-30 | Skinvisible Pharmaceuticals, Inc. | Method for stabilizing retinoic acid, retinoic acid containing composition, and method of using a retinoic acid containing composition |
US9642863B2 (en) | 2010-11-18 | 2017-05-09 | White Mountain Pharma, Inc. | Methods for treating chronic or unresolvable pain and/or increasing the pain threshold in a subject and pharmaceutical compositions for use therein |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
USD750788S1 (en) | 2013-11-26 | 2016-03-01 | Acrux Dds Pty Ltd | Topical spreading applicator |
USD749225S1 (en) | 2013-11-26 | 2016-02-09 | Acrux Dds Pty Ltd | Topical spreading applicator |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
MX2016013693A (es) | 2014-07-29 | 2017-10-31 | Therapeuticsmd Inc | Crema transdermica. |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
EP3435977A4 (en) | 2016-04-01 | 2019-10-16 | Therapeuticsmd, Inc. | PHARMACEUTICAL COMPOSITION OF STEROID HORMONE |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
CA3074150A1 (en) | 2020-02-18 | 2021-08-18 | Ovation Science, Inc. | Composition and method for transdermal delivery of cannabidiol (cbd) and delta9-tetrahydrocannabinol (thc) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63258817A (ja) * | 1987-04-02 | 1988-10-26 | チバ−ガイギー アクチェンゲゼルシャフト | 活性成分の組合せのための経皮的治療システム |
JPH01135727A (ja) * | 1987-11-16 | 1989-05-29 | Macrochem Corp | 新規な経皮的吸収促進剤およびそれを含む組成物 |
JPH03227920A (ja) * | 1989-11-17 | 1991-10-08 | Lab Beta Sa | エストラジオールのための経皮デリバリー装置および該装置の製法 |
JPH0859456A (ja) * | 1994-04-29 | 1996-03-05 | Lab L Lafon Sa | 経皮投与のための新規薬理投与形態 |
JPH08505629A (ja) * | 1993-01-19 | 1996-06-18 | アンドルシェルシュ・インコーポレイテッド | デヒドロエピアンドロステロンの治療用途およびデリバリーシステム |
WO1997029735A1 (en) * | 1996-02-19 | 1997-08-21 | Monash University | Dermal penetration enhancers and drug delivery systems involving same |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704282A (en) * | 1984-06-29 | 1987-11-03 | Alza Corporation | Transdermal therapeutic system having improved delivery characteristics |
US4883669A (en) * | 1985-02-25 | 1989-11-28 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration |
US4861764A (en) * | 1986-11-17 | 1989-08-29 | Macro Chem. Corp. | Percutaneous absorption enhancers, compositions containing same and method of use |
US4788062A (en) * | 1987-02-26 | 1988-11-29 | Alza Corporation | Transdermal administration of progesterone, estradiol esters, and mixtures thereof |
US5118676A (en) * | 1988-04-08 | 1992-06-02 | Whitby Research, Inc. | Penetration enhancers for transdermal delivery of systemic agents |
US5252334A (en) * | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
JP2945993B2 (ja) * | 1989-12-05 | 1999-09-06 | 武田薬品工業株式会社 | 外用剤 |
US5198223A (en) * | 1990-10-29 | 1993-03-30 | Alza Corporation | Transdermal formulations, methods and devices |
US5314694A (en) * | 1990-10-29 | 1994-05-24 | Alza Corporation | Transdermal formulations, methods and devices |
US5512292A (en) * | 1990-10-29 | 1996-04-30 | Alza Corporation | Transdermal contraceptive formulations methods and devices |
US5164190A (en) * | 1990-12-11 | 1992-11-17 | Theratech, Inc. | Subsaturated transdermal drug delivery device exhibiting enhanced drug flux |
US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
US5518734A (en) * | 1991-09-25 | 1996-05-21 | Beta Pharmaceuticals Co. | Transdermal delivery system for estradiol and process for manufacturing said device |
FR2740038B1 (fr) * | 1995-10-20 | 1998-01-02 | Lafon Labor | Composition pour l'administration transdermique |
-
1997
- 1997-10-16 US US08/953,014 patent/US5968919A/en not_active Expired - Fee Related
-
1998
- 1998-10-02 DE DE69828958T patent/DE69828958T2/de not_active Expired - Fee Related
- 1998-10-02 EP EP98952067A patent/EP0971705B1/en not_active Expired - Lifetime
- 1998-10-02 DK DK98952067T patent/DK0971705T3/da active
- 1998-10-02 JP JP52411099A patent/JP2001505930A/ja not_active Ceased
- 1998-10-02 PT PT98952067T patent/PT971705E/pt unknown
- 1998-10-02 CA CA002260185A patent/CA2260185C/en not_active Expired - Fee Related
- 1998-10-02 WO PCT/US1998/020895 patent/WO1999020257A1/en active IP Right Grant
- 1998-10-02 AT AT98952067T patent/ATE288744T1/de not_active IP Right Cessation
- 1998-10-02 ES ES98952067T patent/ES2238094T3/es not_active Expired - Lifetime
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63258817A (ja) * | 1987-04-02 | 1988-10-26 | チバ−ガイギー アクチェンゲゼルシャフト | 活性成分の組合せのための経皮的治療システム |
JPH01135727A (ja) * | 1987-11-16 | 1989-05-29 | Macrochem Corp | 新規な経皮的吸収促進剤およびそれを含む組成物 |
JPH03227920A (ja) * | 1989-11-17 | 1991-10-08 | Lab Beta Sa | エストラジオールのための経皮デリバリー装置および該装置の製法 |
JPH08505629A (ja) * | 1993-01-19 | 1996-06-18 | アンドルシェルシュ・インコーポレイテッド | デヒドロエピアンドロステロンの治療用途およびデリバリーシステム |
JPH0859456A (ja) * | 1994-04-29 | 1996-03-05 | Lab L Lafon Sa | 経皮投与のための新規薬理投与形態 |
WO1997029735A1 (en) * | 1996-02-19 | 1997-08-21 | Monash University | Dermal penetration enhancers and drug delivery systems involving same |
Non-Patent Citations (1)
Title |
---|
JPN7009003241, S.T.P. Pharma sciences, 1991, Vol.1, No.1, pages 89−93 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005519961A (ja) * | 2002-03-11 | 2005-07-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 継続的スルファターゼ阻害プロゲストゲンホルモン補充療法 |
WO2009037813A1 (ja) | 2007-09-20 | 2009-03-26 | Shiseido Company, Ltd. | 経皮吸収製剤 |
JP4825305B2 (ja) * | 2007-09-20 | 2011-11-30 | 株式会社 資生堂 | 経皮吸収製剤 |
US8507467B2 (en) | 2007-09-20 | 2013-08-13 | Shiseido Company, Ltd. | Transdermally absorbable preparation |
Also Published As
Publication number | Publication date |
---|---|
DK0971705T3 (da) | 2005-06-13 |
EP0971705A4 (en) | 2001-01-31 |
EP0971705A1 (en) | 2000-01-19 |
ES2238094T3 (es) | 2005-08-16 |
ATE288744T1 (de) | 2005-02-15 |
CA2260185A1 (en) | 1999-04-17 |
US5968919A (en) | 1999-10-19 |
CA2260185C (en) | 2008-12-23 |
DE69828958D1 (de) | 2005-03-17 |
WO1999020257A1 (en) | 1999-04-29 |
EP0971705B1 (en) | 2005-02-09 |
PT971705E (pt) | 2005-06-30 |
DE69828958T2 (de) | 2006-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001505930A (ja) | 皮膚への局所的施用のためのホルモン代償療法薬剤 | |
JP4825305B2 (ja) | 経皮吸収製剤 | |
EP1674068B1 (en) | Dermal penetration enhancers and drug delivery systems involving same | |
ES2466676T3 (es) | Sistema de administración transdérmica para hormonas y esteroides | |
JP4293293B2 (ja) | エストローゲン、プロゲスチンあるいはそれら混合物の新規なる経皮投与用組成物 | |
US6923983B2 (en) | Transdermal delivery of hormones | |
ES2283425T3 (es) | Nueva composicion para la administracion transdermica y/o transmucosa de compuestos activos que asegura niveles terapeutiocos adecuados. | |
KR100977896B1 (ko) | 제약 조성물 | |
JPH02191214A (ja) | 医薬活性剤の経皮デリバリー用組成物 | |
JP2001503749A (ja) | 透過促進剤としてのグリコール酸の脂肪酸エステル及びその塩 | |
KR890000183B1 (ko) | 경피 침투가 증진된 생리학적 활성 제제 및 그의 제조방법 | |
US20070287688A1 (en) | Pharmaceutical Compositions for Topical Application | |
JP4387639B2 (ja) | 経皮吸収製剤 | |
JPH0244815B2 (ja) | ||
JP2775203B2 (ja) | 吸収促進組成物 | |
JPH06128120A (ja) | 皮膚外用組成物 | |
JP2700990B2 (ja) | 経皮吸収促進物質及び皮膚外用剤組成物 | |
JPH06184000A (ja) | (−)−イソプレゴールからなる経皮吸収促進剤 | |
JPH05178748A (ja) | 皮膚外用液剤 | |
JPH10265409A (ja) | 外用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050928 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20090113 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090707 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091007 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091116 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20100201 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100316 |